TABLE 1 .
Antimicrobial susceptibilities of the key Campylobacter strains used in this study
| Strain | Description | MIC (mg/liter)a of: |
||||
|---|---|---|---|---|---|---|
| FFC | CHL | CIP | ERY | TET | ||
| DH161 | C. coli from duck, isolated in 2009 | 16 | 256 | 256 | 4 | 512 |
| NCTC 11168 | C. jejuni reference strain | 0.5 | 1 | 0.125 | 1 | 1 |
| NT161 | Transformant of NCTC 11168 carrying RE-cmeABC from DH161 | 16 | 16 | 1 | 4 | 4 |
| NT161-aphA-3 | NT161cmeABC::aphA-3 | 0.25 | 0.25 | <0.03 | <0.125 | <0.06 |
| 11168-V1 | NCTC 11168 with RE-cmeABC of NT161 and its promoter sequence | 16 | 16 | 1 | 4 | 4 |
| 11168-V2 | NCTC 11168 with RE-cmeABC of NT161 but original promoter of cmeABC in NCTC 11168 | 4 | 4 | 0.5 | 2 | 2 |
| 81–176 | C. jejuni reference strain | 0.5 | 2 | 0.125 | 0.25 | - |
| 81–176-V | 81-176 with RE-cmeABC of DH161 | 32 | >64 | 1 | 512 | - |
| 11168-C257T | NCTC 11168 with C257T mutation in gyrA | 0.5 | 1 | 16 | 1 | 1 |
| NT161-C257T | NT161 with C257T mutation in gyrA | 16 | 16 | 256 | 4 | 4 |
a
CHL, chloramphenicol; CIP, ciprofloxacin; ERY, erythromycin; FFC, florfenicol; TET, tetracycline.